Oxford Cannabinoid Technologies to list in London to further four drug development programs
Oxford Cannabinoid Technologies Holdings Ltd s co-founder and executive chairman Neil Mahapatra talks to Proactive London ahead of their London initial public offer on Friday 21st May.
The firm have raised £16.5mln to develop cannabis-based pain treatments and are expected to reach a valuation on listing of around £51mln.
With the company focussed on medicines that mimic the painkilling effects of cannabis, it plans to use the funds raised in the IPO to help develop a portfolio of four drug candidates for approval as licensed pain medicines, with the aim of commercializing the company s first drug in 2027.
London, U.K. – Nobody is more synonymous with smoking weed than Snoop Dogg at this point. Snoop turned his love for pot into lucrative business opportunities and one of the Cannabinoid companies he’s financially backing will be going public on the London Stock Exchange by the end of this week, according to
Oxford Cannabinoid Technologies which is a pharmaceutical company developing cannabinoid-based prescription medicines revealed on Tuesday (May 18) it had raised $23.4 million from investors ahead of going public.
Oxford Cannabinoid Technologies, a firm that develops cannabinoid-based prescription medicine and is backed by Snoop Dogg will list on London’s main market later this week.